Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage

Lotte Sondag, MD,¹ Floris H. B. M. Schreuder, MD,¹ Hieronymus D. Boogaarts, MD, PhD,² Maroeska M. Rovers, PhD,³ W. Peter Vandertop, MD, PhD,⁴,⁵ Ruben Dammers, MD, PhD,⁶ and Catharina J. M. Klijn, MD, PhD,⁷ on behalf of the Dutch ICH Surgery Trial Study Group, part of the CONTRAST consortium†

Objective: The effect of surgical treatment for supratentorial spontaneous intracerebral hemorrhage (ICH) and whether it is modified by key baseline characteristics and timing remains uncertain.

Methods: We performed a systematic review and meta-analysis of randomized controlled trials of surgical treatment of supratentorial spontaneous ICH aimed at clot removal. We searched MEDLINE, Embase, and Cochrane databases up to February 21, 2019. Primary outcome was good functional outcome at follow-up; secondary outcomes were death and serious adverse events. We analyzed all types of surgery combined and minimally invasive approaches separately. We pooled risk ratios with 95% confidence intervals and assessed the modifying effect of age, Glasgow Coma Scale, hematoma volume, and timing of surgery with meta-regression analysis.

Results: We included 21 studies with 4,145 patients; 4 (19%) were of the highest quality. Risk ratio of good functional outcome after any type of surgery was 1.40 (95% confidence interval [CI] = 1.22–1.60, I² = 46%, 20 studies), and after minimally invasive surgery it was 1.47 (95% CI = 1.26–1.72, I² = 47%, 12 studies). For death, the risk ratio for any type of surgery was 0.77 (95% CI = 0.68–0.85, I² = 23%, 21 studies), and for minimally invasive surgery it was 0.68 (95% CI = 0.56–0.83, I² = 14%, 13 studies). Serious adverse events were reported infrequently. Surgery seemed more effective when performed sooner after symptom onset (p = 0.04, 12 studies). Age, Glasgow Coma Scale, and hematoma volume did not modify the effect of surgery.

Interpretation: Surgical treatment of supratentorial spontaneous ICH may be beneficial, in particular with minimally invasive procedures and when performed soon after symptom onset. Further well-designed randomized trials are needed to demonstrate whether (minimally invasive) surgery improves functional outcome after ICH and to determine the optimal time window of the treatment after symptom onset.

A acute nontraumatic spontaneous intracerebral hemorrhage (sICH), accounts for 15 to 20% of all strokes in the Western population and for 20 to 50% in developing countries.¹⁻³ ICH is the deadliest stroke subtype, with a 30-day case fatality of approximately 40%.⁴ Rapid identification and treatment are essential to

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25732

Received Jul 31, 2019, and in revised form Mar 11, 2020. Accepted for publication Mar 22, 2020.

Address correspondence to Dr Klijn, Department of Neurology, Radboud University Medical Center, Reinier Postlaan 4, PO-box 9101, 6500HB Nijmegen, the Netherlands. E-mail: karin.klijn@radboudumc.nl

†A complete list of the members of the Dutch ICH Surgery Trial Study Group appears after the Author contributions.

From the ¹Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; ²Department of Neurosurgery, Radboud University Medical Center, Nijmegen, the Netherlands; ³Departments of Operating Rooms and Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands; ⁴Department of Neurosurgery, Neurosurgical Center Amsterdam, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, the Netherlands; ⁵Department of Neurosurgery, Neurosurgical Center Amsterdam, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands; and ⁶Department of Neurosurgery, Erasmus Medical Center, Erasmus MC Stroke Center, Rotterdam, the Netherlands

Additional supporting information can be found in the online version of this article.

© 2020 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. 239 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
facilitate recovery. However, of patients surviving, only few gain independence. Apart from the effect of stroke unit care and early control of elevated blood pressure, which may be beneficial, there are no treatments with proven benefit. A recent study showed that implementation of a hyperacute care bundle (anticoagulation reversal, intensive blood pressure lowering, neurosurgery in selected patients, access to critical care), reduces case fatality.

The role of surgery in supratentorial sICH remains controversial. This is reflected in the American and European guidelines, which refrain from giving firm advice regarding the role of surgery in ICH. As a result, there is large variation in clinical practice. The landmark trials STICH and STICH II failed to demonstrate a beneficial effect of surgical treatment, mostly craniotomy, but surgery was performed late, on average 30 hours after symptom onset in STICH and 58 hours in STICH II. In the STICH trials, crossover from the control arm to surgery was allowed if a patient deteriorated. Increasing evidence suggests that with minimally invasive procedures the potentially adverse effect of open surgery in patients with sICH can be avoided and a beneficial effect on functional outcome may be achieved. An individual patient data meta-analysis of randomized controlled trials (RCTs) published up to 2010 suggested that the effect of surgery may be modified by the clinical state of the patient and the timing of surgery, but in this analysis only a minority of patients were treated with minimally invasive techniques. Recently, the MISTIE III trial showed that minimally invasive hematoma aspiration with local application of alteplase up to 72 hours after surgery did not seem to be superior to standard medical care. However, surgery in this trial was also performed late, on average 58 hours after symptom onset.

Approximately one-quarter of patients with ICH show hematoma growth, with the highest probability of growth within the first 3 hours after symptom onset. Besides the direct brain injury by compression and disruption of parenchyma, sICH elicits a secondary response. This secondary brain injury results from toxicity due to blood degradation products (eg, heme, iron) and plasma-derived components (eg thrombin), which starts within 3 to 4 hours after sICH, causing an inflammatory response and the development of perihematomal edema. Hematoma volume, hematoma growth, and perihematomal edema are independent predictors of poor outcome. Targeting hematoma growth, inflammation, and perihematomal edema at an early stage after sICH may reduce not only hematoma volume but also secondary brain injury, and could possibly improve outcome. However, a previous pilot study of “ultra-early” surgery within 4 hours after sICH in 20 patients was stopped early after a planned interim analysis in 11 patients because of postoperative bleeding in 4 patients, in 3 of them fatal. Others found no difference in rebleeding rates between stereotactic treatment within (mean = 4.8 h, 32 patients, 1 rebleed) vs after 6 hours (mean = 13.8 h, 27 patients, 2 rebleeds) from symptom onset in computed tomography (CT) angiographic spot sign–negative patients, suggesting that early surgery may be safe in patients with ICH in the absence of a spot sign.

We aimed to systematically review and meta-analyze RCTs of surgical treatment of supratentorial sICH aimed at clot removal, both overall and for minimally invasive treatment separately, and to assess the modifying effect of age, Glasgow Coma Score (GCS), hematoma volume, and timing of surgery.

**Patients and Methods**

We adhered to the PRISMA guidelines and registered the study protocol in PROSPERO (CRD42018098864).

**Search Strategy and Selection Criteria**

We searched MEDLINE, Embase, and Cochrane databases up to February 21, 2019. We included RCTs on the effect of neurosurgical hematoma evacuation, compared with standard medical management on functional outcome and death, in adult patients (≥18 years of age) with a CT or magnetic resonance scan-confirmed supratentorial sICH. Neurosurgical intervention could consist of craniotomy, craniopuncture, stereotactic aspiration, endoscopy-guided aspiration with or without local clot mobilization techniques using thrombolytic agents, or alternative methods. Treatment of hydrocephalus with extraventricular drainage (EVD) alone was not included as an intervention of interest and was allowed in both groups. Duration of follow-up in the trial had to be at least 3 months. We excluded studies that included patients with secondary causes of ICH (ie, hemorrhage due to trauma, aneurysm, arteriovenous malformation and dural arteriovenous fistula, cavernous malformation and tumor) or infratentorial hemorrhages (unless separately reported) and if ≥15% of the surgical interventions were decompressive hemicraniectomies without hematoma removal. Conference abstracts were excluded. We did not apply any language restriction. The search strategy consisted of terms for supratentorial ICH and terms for surgical treatment or hematoma evacuation. We identified further studies from the reference lists of included papers and screened reference lists of review articles. Finally, we searched ClinicalTrials.gov, the International Standard Randomized Controlled Trial Number registry, and the https://www isrctn com/ database for clinical trials, and ClinicalTrialsRegister.eu for unpublished studies.
Two authors (L.S. and F.H.B.M.S) independently screened the abstracts and assessed full texts to identify studies that potentially met the predefined inclusion and exclusion criteria. Any disagreements between these authors were resolved by a third reviewer (C.J.M.K.). For articles written in Chinese, we received help from 2 native Chinese colleagues.

Data Synthesis and Statistical Analyses
Two authors (L.S. and F.H.B.M.S) independently extracted data from the included studies, using a standardized, prepiloted form, and assessed the risk of bias using the following items from the Cochrane criteria: random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data, selective reporting, and performance of an intention-to-treat analysis.26 Because blinding to treatment of participants and personnel is not feasible in a neurosurgical trial, we discarded this item. Disagreements on extracted data were resolved by discussion with a third reviewer (C.J.M.K.).

We extracted the following baseline characteristics: sex, mean or median age and age range, clinical condition on admission measured by the mean or median GCS and range, proportion with a history of hypertension, ICH location, mean or median ICH volume and range, presence of intraventricular hemorrhage, surgical technique, mean or median time from symptom onset to surgery and range, and proportion of patients who crossed over from control to intervention.

The prespecified primary outcome was good functional outcome at 3-month follow-up. Because the timing of the primary outcome event in the included studies varied from 3 to 12 months, we assessed whether the effect size of surgery differed in studies reporting outcomes at 3, 6, and 12 months. Because the estimates of surgery appeared similar for all time points, we combined all studies, using 6 months as the preferred time point (available in most studies), and we used 3 or 12 months if the 6-month outcome was not provided. We defined good functional outcome as a modified Rankin Scale score of 0 to 3, a Glasgow Outcome Scale score of 4 to 5, an extended Glasgow Outcome Scale score of 5 to 8, or a Barthel Index (BI) of ≥60. In studies that did not report any of these outcomes, we used the scale and cutoff points for good functional outcome as reported by the authors.

Secondary outcomes were death at 6 months (or when not available at 3 or 12 months), case fatality at 30 days, and serious adverse events within 30 days, including rebleeding, epileptic seizures, intracranial infection, hydrocephalus, severe systemic infection, gastrointestinal bleed, need for (repeated) surgical intervention, and EVD.

We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for good functional outcome and death at the time of follow-up, using a random effects model for all surgical procedures, for studies on minimally invasive surgery, and for studies on (>99%) craniotomy. We performed a sensitivity analysis assessing high-quality studies only, defined as studies with a low risk of bias on all items as determined by the Cochrane risk of bias tool. We assessed heterogeneity by means of the I-squared statistic (I²) and categorized heterogeneity as follows: 0 to 40%, heterogeneity that might not be important; 30 to 60%, moderate heterogeneity; 50 to 90%, substantial heterogeneity; and 75 to 100%, considerable heterogeneity. In addition, we calculated prediction intervals, which help in the clinical interpretation of heterogeneity by estimating the expected range of true effects in similar studies. They can be used as a tool for interpreting evidence and enable more informed clinical decision-making.27 We performed a sensitivity analysis for good functional outcome at follow-up, excluding the 2 studies that used BI as outcome measure. We constructed funnel plots to evaluate potential publication bias.

We performed meta-regression analysis for the primary outcome to assess the effect of 4 prespecified factors that have previously been suggested to influence the effect of surgery15–17: age (mean, or when not available median age), GCS (median, or when not available mean GCS), time from symptom onset to surgery, and ICH volume (mean, or when not available median ICH volume). We performed meta-regression for these potential modifying factors only if there were at least 10 studies available that reported that specific factor; further multivariate meta-regression analysis was performed if at least 10 studies were available for every modifying factor included (eg, 20 studies for analysis of 2 factors).26,28,29 In addition, we assessed the effect of surgery in subgroups according to ICH location (lobar vs nonlobar), because the effect of surgery appeared to be different in lobar than in deep ICH in STICH.15 Finally, we summarized the reported percentages of adverse events.

We used the software program R and R-studio version 3.4.4, packages “meta,” “metafor,” and “foreign.”

Results
We identified 21 studies (Fig 1) including 4,145 patients, of whom 2,091 were randomized for neurosurgical hematoma evacuation and 2,054 patients for standard medical management. One eligible study did not provide data on functional outcome and was excluded for the meta-analysis on good functional outcome.30 The Table summarizes the characteristics of the included studies. Inclusion criteria for the
individual RCTs are listed in the supplement (Supplementary Table 4). Of the 21 studies, 13 studies assessed minimally invasive surgical approaches, \(^1\) \(^8\) \(^{30}\) \(^{32}\) \(^{36}\) \(^{42}\) \(^{44}\) \(^{45}\) in 6 of them in combination with a thrombolytic agent. \(^1\) \(^8\) \(^{31}\) \(^{37}\) \(^{41}\) \(^{42}\) \(^{45}\) One study included patients with lobar ICH only, \(^1\) \(^6\) and 7 studies were restricted to patients with deep ICH. \(^{30}\) \(^{34}\) \(^{38}\) \(^{39}\) \(^{41}\) \(^{42}\) \(^{44}\) Nine studies specified whether thalamic hemorrhages were included. \(^{16}\) \(^{18}\) \(^{31}\) \(^{33}\) \(^{35}\) \(^{36}\) \(^{39}\) \(^{43}\) Four studies included 12 to 23% thalamic hemorrhages, \(^{33}\) \(^{35}\) \(^{36}\) \(^{39}\) and 3 did not include thalamic hemorrhages. \(^{16}\) \(^{34}\) \(^{43}\) Intraventricular extension of ICH was an exclusion criterion in 1 study. \(^1\) \(^6\) Quality of studies was low in 9 studies, \(^{30}\) \(^{32}\) \(^{34}\) \(^{36}\) \(^{38}\) \(^{40}\) \(^{45}\) and moderate in 8 studies. \(^{33}\) \(^{37}\) \(^{41}\) \(^{44}\) \(^{46}\) \(^{47}\) Only 4 studies were of high quality, \(^{15}\) \(^{16}\) \(^{18}\) \(^{31}\) of which 2 investigated minimally invasive surgery (Fig 2). \(^{18}\) \(^{31}\) The funnel plot suggested possible publication bias for smaller studies demonstrating results in favor of medical management (Fig 3). Six to 26% of patients randomized for standard medical management crossed over to surgical hematoma evacuation (10 studies). \(^{15}\) \(^{16}\) \(^{18}\) \(^{31}\) \(^{33}\) \(^{38}\) \(^{39}\) \(^{41}\) \(^{43}\) \(^{46}\) Data on functional outcome were available in 1,967 (99.5%) patients randomized to surgery and in 1,919 (99.3%) patients randomized to standard medical management. After surgical treatment, the chance of good functional outcome was 40% higher than after medical management (RR = 1.40, 95% CI = 1.22–1.60, \(I^2 = 46\%\); Fig 4). Estimates for subgroups of studies with outcome assessment at 3, 6, and 12 months are listed in Appendix S1 (see Supplementary Table 1). Surgical treatment also lowered the risk of death (RR = 0.77, 95% CI = 0.68–0.85, \(I^2 = 21\%\),}
at the time of follow-up. The RR for 30-day case fatality after any type of surgery was 0.68 (95% CI = 0.51–0.92, $I^2 = 0\%$, 5 studies). The chance of good functional outcome after minimally invasive surgery was 47% higher than after medical management (RR = 1.47, 95% CI = 0.69–2.93, $I^2 = 48\%$, 6 studies), RR for death was 0.79 (95% CI = 0.66–0.94, $I^2 = 0\%$, 6 studies), and RR for 30-day case fatality was 0.73 (95% CI = 0.61–0.82, $I^2 = 26\%$, 2 studies; Supplementary Table 2). When we restricted the analyses to high-quality studies (2 studies assessing mostly

21 studies) at the time of follow-up. The RR for 30-day case fatality after any type of surgery was 0.68 (95% CI = 0.51–0.92, $I^2 = 0\%$, 5 studies). The chance of good functional outcome after minimally invasive surgery was 47% higher than after medical management (RR = 1.47, 95% CI = 0.69–2.93, $I^2 = 48\%$, 6 studies), RR for death was 0.79 (95% CI = 0.66–0.94, $I^2 = 0\%$, 6 studies), and RR for 30-day case fatality was 0.73 (95% CI = 0.61–0.82, $I^2 = 26\%$, 2 studies; Supplementary Table 2). When we restricted the analyses to high-quality studies (2 studies assessing mostly

...
### TABLE. Baseline Characteristics of 21 Randomized Controlled Trials Meeting Inclusion Criteria

| Study         | P, n | C, n | Type of Surgery | Use of Thrombolytic Agent, % of Patients | Age, Mean yr | Male, n (%) | GCS, Median (IQR) | Deep ICH, n (%) | Onset to Surgery, Mean h | IVH, n (%) |
|---------------|------|------|-----------------|-----------------------------------------|--------------|-------------|-------------------|----------------|--------------------------|------------|
| Auer 1989     | 36   | 50   | Endoscopy-guided| No                                      | NR           | 61 (61)     | NR                | 55 (55)        | NR                       | NR         |
| Juvela 1989   | 26   | 26   | Craniotomy      | NA                                      | 52           | 30 (58)     | 12 (7–14)         | 44 (85)        | 14.5⁴ (32 (62%))         | NR         |
| Batjer 1990   | 8    | 13   | Craniotomy      | NA                                      | 55           | NR          | NR                | 21 (100)       | NR                       | NR         |
| Morgenstern 1998 | 17  | 17   | Craniotomy      | NA                                      | 51b          | 22 (65)     | 11 (10–14)        | 26 (76)        | 8.3⁴ (55%)                | NR         |
| Zuccarello 1999 | 9   | 11   | Craniotomy, n = 5; stereotactic, n = 4 | Urokinase in stereotactic | 62           | 11 (55)     | 12 (9–14)         | 10 (50)        | 8.6⁴ (55%)              | NR         |
| Ternstra 2003 | 34   | 36   | Stereotactic    | Urokinase (100%)                        | 68           | 40 (57)     | 9 (7–11)          | 32 (46)        | 12                       | 23 (33%) |
| Hattori 2004  | 121  | 121  | Stereotactic    | No                                      | 61           | 148 (61)    | NR                | 242 (100)      | NR                       | NR         |
| Mendelow 2005 | 530  | 503  | Craniotomy 75%  | NR                                      | 62b          | 591 (57)    | 12 (9–14)         | 434 (42)       | 30b                      | NR         |
| Pantazis 2006 | 54   | 54   | Craniotomy      | NA                                      | 61           | 60 (56)     | 9⁵                 | 57 (53)        | 6.2⁴ (60%)               | NR         |
| Cho 2008      | 113  | 113  | Endoscopy-guided| No                                      | 63           | 151 (67)    | 11                | 226 (100)      | 72 (32%)                 | NR         |
| Luo 2008      | 39   | 36   | Aspiration      | No                                      | 55           | 44 (59)     | NR                | 75 (100)       | NR                       | NR         |
| Miller 2008   | 6    | 4    | Endoscopy-guided| No                                      | 59           | 9 (90)      | NR                | 1 (10)         | 18                       | 6 (60%) |
| Young 2009    | 204  | 183  | Stereotactic    | Urokinase in 26%                        | 66           | 289 (75)    | 14 (14–15)        | 387 (100)      | NR                       | NR         |
| Wang 2009     | 195  | 182  | Stereotactic    | Urokinase (100%)                        | 56           | 236 (63)    | 12 (10–14)        | 377 (100)      | 21                       | 70 (19%) |
| Wei 2010      | 67   | 39   | Various techniques⁴ | Urokinase (100%)                      | 57b          | 58 (55)     | NR                | NR (60)        | NR                       | NR         |
| Wang 2011     | 32   | 30   | Craniopuncture  | No                                      | 46           | 34 (55)     | NR                | 62 (100)       | 8.2                      | NR         |
| Mendelow 2013 | 305  | 292  | Craniotomy 99%  | NA                                      | 64           | 340 (57)    | 13 (12–15)        | 0 (0)          | 26.7                     | 0 (0%)    |
| Hanley 2016   | 54   | 42   | Stereotactic    | Alteplase (85%)                         | 61           | 63 (66)     | NR                | 63 (66)        | NR                       | NR         |
| Vespa 2016    | 14   | 42   | Endoscopy-guided| No                                      | NR           | 37 (66)     | NR                | 39 (70)        | 29.9⁴ (51%)              | NR         |
| Bhaskar 2017  | 34   | 27   | Craniotomy      | NA                                      | 55           | 37 (61)     | NR                | 52 (85)        | 31 (51%)                 | NR         |
| Hanley 2019   | 250  | 249  | Stereotactic    | Alteplase (94%)                         | 305 (61)     | 62 (52–70)  | 307 (62)          | 58.3           | NR                       | NR         |

⁴Median time between symptom onset and surgery.
⁵Data reported as median age.
⁶Data reported as mean GCS.
⁷Small skull window microsurgery was performed in 31 patients and minimally invasive surgery fragmenting and aspirating hematoma in 36 patients.
C = controls; GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; IQR = interquartile range; IVH = intraventricular hemorrhage; NA = not applicable; NR = not reported; P = patients, surgically treated.
FIGURE 5: Effect of minimally invasive surgery compared with standard medical management on good functional outcome in patients with supratentorial spontaneous intracerebral hemorrhage. Functional outcome was assessed at 6 months after inclusion if available. For 2 studies (Hattori 2004 and Hanley 2019), functional outcome at 12 months after inclusion was used, and for 2 studies (Wang 2009 and Wei 2010), functional outcome at 3 months after inclusion was used. CI = confidence interval; RR = risk ratio. [Color figure can be viewed at www.annalsofneurology.org]

FIGURE 6: Effect of any type of surgery compared with standard medical management on good functional outcome in patients with supratentorial spontaneous intracerebral hemorrhage in high-quality studies only. Functional outcome was assessed at 6 months after inclusion, except for 1 study (Hanley 2019) in which functional outcome at 12 months after inclusion was used. CI = confidence interval; RR = risk ratio. [Color figure can be viewed at www.annalsofneurology.org]

FIGURE 7: Influence of timing of surgery on the effect of surgery on good functional outcome. $\beta = -0.0063$, $p = 0.04$. Mean or, if not available, median time from symptom onset to surgery was used to assess the influence of time from symptom onset to surgery on the effect of any type of surgery on good functional outcome, in 12 studies. The size of each circle is proportional to the precision of each log risk ratio estimate. MIS = minimally invasive surgery.
cral operation, including a total of 2,166 patients. RRs for good functional outcome (RR = 1.10, 95% CI = 0.98–1.25, \( I^2 = 0\% \); Fig 6) and death (RR = 0.86, 95% CI = 0.72–1.03, \( I^2 = 3\% \), 4 studies) no longer showed a statistically significant effect of surgical treatment. Sensitivity analyses excluding 2 studies that used BI as outcome measure showed similar results for the chance of good functional outcome at follow-up (any type of surgery: RR = 1.43, 95% CI = 1.22–1.69, \( I^2 = 51\% \), 18 studies; minimally invasive surgery: RR = 1.54, 95% CI = 1.27–1.87, \( I^2 = 49\% \), 11 studies).

We found no statistically significant modifying influence of age (18 studies, \( p = 0.61 \)), GCS score on admission (13 studies, \( p = 0.97 \)), or ICH volume (15 studies, \( p = 0.50 \)) on good functional outcome at the time of follow-up (Supplementary Table 3). Surgery seemed more effective than medical management alone when performed sooner after the onset of symptoms (12 studies, \( p = 0.04 \); Fig 7). We found no modifying effects of age (19 studies, \( p = 0.43 \)), GCS (14 studies, \( p = 0.29 \)), ICH volume (15 studies, \( p = 0.32 \)), or timing of surgery (12 studies, \( p = 0.37 \)) on death. Because any combination of modifying factors was reported in <20 studies, we refrained from further multivariate meta-regression analysis.

The number of studies that assessed minimally invasive surgery and reported modifying factors was <10, which precluded meta-regression analysis in this subgroup. In the subgroup of patients with ongoing bleeding in the group that underwent hematoma evacuation (12 studies), \( 16,18,31,32,37,41,42 \) no longer showed a statistically significant effect of surgical treatment. Sensitivity analyses excluding 2 studies that used BI as outcome measure showed similar results for the chance of good functional outcome at follow-up (any type of surgery: RR = 1.43, 95% CI = 1.22–1.69, \( I^2 = 51\% \), 18 studies; minimally invasive surgery: RR = 1.54, 95% CI = 1.27–1.87, \( I^2 = 49\% \), 11 studies).

We found no statistically significant modifying influence of age (18 studies, \( p = 0.61 \)), GCS score on admission (13 studies, \( p = 0.97 \)), or ICH volume (15 studies, \( p = 0.50 \)) on good functional outcome at the time of follow-up (Supplementary Table 3). Surgery seemed more effective than medical management alone when performed sooner after the onset of symptoms (12 studies, \( p = 0.04 \); Fig 7). We found no modifying effects of age (19 studies, \( p = 0.43 \)), GCS (14 studies, \( p = 0.29 \)), ICH volume (15 studies, \( p = 0.32 \)), or timing of surgery (12 studies, \( p = 0.37 \)) on death. Because any combination of modifying factors was reported in <20 studies, we refrained from further multivariate meta-regression analysis.

The number of studies that assessed minimally invasive surgery and reported modifying factors was <10, which precluded meta-regression analysis in this subgroup. In the subgroup of patients with deep ICH, the RR of good functional outcome after surgery compared to medical management was 1.51 (95% CI = 1.31–1.75, \( I^2 = 25\% \), 9 studies), and in those with lobar hemorrhages it was 1.25 (95% CI = 0.92–1.71, \( I^2 = 13\% \), 4 studies). Reporting of adverse and serious adverse events varied among studies (Supplementary Table 5). In surgically treated patients, a second surgical procedure was needed in 4 to 16% of patients (5 studies). \( 15,18,31,33,34 \) Rebleeding occurred in 0 to 50% of medically treated patients (12 studies), \( 16,18,31,33,36,38,40,42,43,45 \) and in 0 to 35% of surgically treated patients (13 studies). \( 16,18,31,33,36,40,42,43,45 \) Three studies reported a higher frequency of rebleeds in the group randomized to medical management than in those who received surgery, \( 16,36,45 \) whereas 5 studies found more rebleeds in the group that underwent hematoma evacuation. \( 18,31,32,37,42 \) Four of these 5 studies used local application of a thrombolytic agent to optimize the evacuation of the hematoma. \( 18,31,37,42 \) Operative site infections were rare. \( 18,31,33,38 \)

**Discussion**

Our meta-analysis shows that neurosurgical hematoma evacuation in patients with supratentorial sICH holds promise to improve functional outcome and death at 3 to 12 months, but only the minority of studies was without bias. The effect of hematoma evacuation appears most prominent with application of minimally invasive techniques and when performed sooner rather than later after symptom onset. We found no modifying effect of age, clinical state on admission, and ICH volume. In the 4 RCTs of high quality, the effect of neurosurgical hematoma evacuation on functional outcome and on death was no longer statistically significant.

One of the important factors for why earlier high-quality RCTs may have failed to demonstrate a beneficial effect of surgical hematoma evacuation for supratentorial sICH is the timing of the surgical treatment. In the previous individual patient data meta-analysis of RCTs published up to 2010 that suggested that earlier surgery may increase the benefit of intervention, the time interval between symptom onset and randomization in the included studies was still long. \( 17 \) Approximately 40% of patients who had a known time interval from onset to randomization were randomized within 8 hours, approximately 30% between 8 and 24 hours, and approximately 30% >24 hours after symptom onset. Time intervals between symptom onset and surgery were not reported, but most likely only few patients will have had their hematoma evacuation within 6 hours after symptom onset in all trials, and even fewer within 3 hours after symptom onset. \( 46 \) Compared to the individual patient data meta-analysis, we were able to include more studies, \( 16,18,30–32,34,38,41,43,45,47 \) among which are studies with earlier treatment and studies that tested minimally invasive approaches. \( 18,30–32,38,41,44,45 \) As one-quarter of patients with ICH show hematoma growth consistent with ongoing bleeding in the first hours after symptom onset, some neurosurgeons advocate postponing surgical intervention until the hematoma has stabilized. \( 23,24 \) The nonrandomized pilot study of “ultra-early” open craniotomy and hematoma evacuation (median time to surgery = 180 minutes) showed rebleeding in 4 of 11 patients and was therefore stopped early. \( 23 \) A recent study suggested that stereotactic aspiration within 6 hours after symptom onset may be safe in patients with sICH in the absence of a spot sign. \( 24 \) However, it should be noted that in a recent individual patient data meta-analysis of 5,435 patients assessing prediction of hematoma growth, the addition of the CT angiography spot sign to a prediction model with time from symptom onset, ICH volume, anticoagulant use, and anti-platelet use improved the C-index only slightly (from 0.78, 95% CI = 0.75–0.82 to 0.83, 95% CI = 0.80–0.86). \( 19 \) The risks of early hematoma growth and rebleeding after ultra-early surgery have shaped the inclusion criterion of proof of a stable ICH volume before starting any type of surgery in recent and ongoing RCTs (MINd, NCT03342664). \( 18,31,32 \)
and an ongoing nonrandomized trial (INVEST, NCT02654015). However, theoretically early surgery could also have additional benefits, such as prevention of ICH growth, additional mass effect and raised intracranial pressure, and amelioration of the secondary brain injury resulting from the toxic effect of blood degradation products and the inflammatory response after ICH. If the timing of surgery is a key success factor, this would favor minimally invasive techniques without the use of thrombolytic agents over procedures that include a time-consuming thrombolysis of the hematoma to reach optimal evacuation. In MISTIE III, surgical treatment was started on average 58.3 hours after symptom onset, the first dose of alteplase was administered after on average 72.6 hours, and treatment was completed after on average after 123 hours.18 The prespecified subgroup analysis on timing in the MISTIE III trial showed no effect of timing of treatment, but none of the patients was treated within 24 hours. Furthermore, results of any meta-regression analysis should be interpreted with caution, because they are observational associations based on averages at the study level and not based on individual patient data, and the included studies have different inclusion and exclusion criteria. Based on the combined evidence of this systematic review and meta-regression and that of others, further well-designed randomized studies should be performed in both the earlier and later time windows. The Dutch ICH Surgery Trial pilot study (NCT03608423; part of the CONTRAST consortium; Dutch-ICH.nl) is currently assessing safety, technical effectiveness, and feasibility of minimally invasive endoscopy-guided surgery for sICH within 8 hours of symptom onset, whereas others are assessing the effect of minimally invasive surgery within 24 hours (MIND, NCT03342664; INVEST, NCT02654015; ENRICH, NCT02880878). Early treatment after sICH may pose a logistical challenge in particular in countries with large distances between patients and neurosurgical centers. Public policies of reimbursement of treatment only for patients who are included in a randomized controlled trial may boost recruitment rates.45

In contrast with the previous individual patient data meta-analysis,17 we did not find a modifying effect of age or the clinical state of the patient at admission. Based on the results of our meta-regression analysis, we suggest that there is no reason to exclude elderly patients from inclusion in future RCTs, or to restrict inclusion to patients on the basis of their GCS score. However, meta-regression analysis is based on observational relations using averages of potential modifying factors within studies and accordingly limited ranges of the modifying factors. Therefore, the observed relations across studies can be subject to confounding by other characteristics that vary between the studies, and relations may not be undoubtedly causal (ecological bias). Furthermore, the small number of studies that reported modifying factors precluded multivariate meta-regression analysis. Individual patient data meta-analysis of all studies included in our meta-analysis could strengthen our findings. STICH suggested a potential modifying effect of sICH location in favor of lobar hemorrhages over deep sICH,15 but this could not be confirmed by STICH II,16 nor by the individual patient data meta-analysis.17 In contrast, our subgroup analysis showed a beneficial effect of hematoma evacuation in patients with deep hemorrhages, but not in those with lobar hemorrhages. A possible explanation is that the modifying effect of location may vary between craniotomy and minimally invasive hematoma evacuation.

Our study has several strengths. First, we performed a comprehensive literature search without any language or publication date restrictions. Second, we assessed the effect of surgery aimed at hemorrhage evacuation overall, as well as of minimally invasive techniques separately. Third, we performed a sensitivity analysis in high-quality studies and were able to assess modifying factors through meta-regression analysis. Finally, in contrast to previous systematic reviews on minimally invasive surgery,49,51,52 we excluded studies that compared minimally invasive techniques to craniotomy.

Our study also has limitations, the most important being the moderate to low quality of some of the included studies. Only 5 studies performed blinded outcome assessments,15,16,18,31,44 and only 4 studies were of high quality overall.15,16,18,31 In addition, crossover to surgery was high in some studies,15,16,38,39 and not reported in many.32,34–37,40,42,44,45,47 Another limitation is that studies varied with respect to timing of both surgery and outcome assessment, the definition of good functional outcome, and the reporting of adverse events. Finally, the use of averages of potential modifying factors in studies, and not individual patient data in meta-regression analysis, could have led to ecological bias. Because of this, we refrained from translating the association to an estimate in
terms of a quantitative effect per hour earlier that surgery is commenced. Individual patient data meta-analysis of the published RCTs could further inform us on whether a larger benefit may be expected in specific subgroups, with specific surgical approaches, or in a specific time-window, without having the possible disadvantages of a meta-regression analysis.

Taken together and despite the recent neutral results of MISTIE III, the results of our systematic review and meta-analysis suggest that surgical treatment may be beneficial to improve outcome in patients with supratentorial sICH, in particular with minimally invasive procedures and when performed early after symptom onset. However, because of the methodological shortcomings and high risk of bias of most included studies, hematoma evacuation cannot be recommended as standard treatment until further high-quality RCTs have firmly proven its effect. Such trials should have a large sample size, high adherence to the intervention, focused hypothesis-testing, and blinded outcome assessment. Physicians involved in the care of patients with ICH should be encouraged to enroll patients with a supratentorial sICH in trials investigating the benefit of (minimally invasive) surgery.

Acknowledgment
We acknowledge the support of the Netherlands Cardiovascular Research Initiative, which is supported by the Dutch Heart Foundation (CVON2015-01: CONTRAST) and the Brain Foundation Netherlands (HA2015.01.06). C.J.M.K. and F.H.B.M.S. are supported by a clinical established investigator grant of the Dutch Heart Foundation (2012 T077) and C.J.M.K. by an ASPASIA grant from the Netherlands Organization for Health Research and Development (ZonMW; 015008048).

We thank Drs W. Sun and B. Fan for their help translating the Chinese articles.

The Dutch ICH Surgery Trial Study Group approved this article.

Author Contributions
L.S., F.H.B.M.S., H.D.B., M.M.R., R.D., and C.J.M.K. contributed to the conception and design of the study; L.S., F.H.B.M.S., M.M.R., R.D., and C.J.M.K. contributed to the acquisition and analysis of data; all authors contributed to drafting the text and preparing the figures.

The Dutch ICH Surgery Trial Study Group consists of J. Coutinho, MD, PhD, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Prof D. Dippel, MD, PhD, Erasmus MC University Medical Center, Rotterdam, the Netherlands; W. A. Moojen, MD, PhD, Haaglanden Medical Center, the Hague, the Netherlands; J. Boiten, MD, PhD, Haaglanden Medical Center, the Hague, the Netherlands; I. van den Wijngaard, MD, PhD, Haaglanden Medical Center, the Hague, the Netherlands; R. W. Koot, MD, PhD, Leiden University Medical Center, Leiden, the Netherlands; Prof M. J. H. Wermer, MD, PhD, Leiden University Medical Center, Leiden, the Netherlands; O. Teernstra, MD, PhD, Maastricht University Medical Center, Maastricht, the Netherlands; I. de Ridder, MD, PhD, Maastricht University Medical Center, Maastricht, the Netherlands; K. H. Kho, MD, Medical Spectrum Twente, Enschede, the Netherlands; P. J. A. M. Brouwers, MD, PhD, Medical Spectrum Twente, Enschede, the Netherlands; B. van der Pol, MD, PhD, Elisabeth–Two Cities Hospital, Tilburg, the Netherlands; P. L. M. de Kort, MD, PhD, Elisabeth–Two Cities Hospital, Tilburg, the Netherlands; Prof A. van der Zwan, MD, PhD, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands; Prof L. J. Kappelle, MD, PhD, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands; H. M. den Hertog, MD, PhD, Isala Hospital, Zwolle, the Netherlands; D. Nanda, MD, PhD, Isala Hospital, Zwolle, the Netherlands (http://www.dutch-ich.nl).

References
1. Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8:355–369.
2. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of first-ever ischaemic and haemorrhagic stroke in 1990–2013: the GBD study. Neuroepidemiology 2015;45:161–176.
3. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet Glob Health 2013;1:e259–e281.
4. van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9:167–176.
5. Gross BA, Jankowitz BT, Friedlander RM. Cerebral Intraparenchymal hemorrhage: a review. JAMA 2019;321:1295–1303.
6. Poon MT, Fonville AF, Al-Shahi SR. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2013;84:560–567.
7. Langhorne P, Fearon P, Rooning OM, et al. Stroke unit care benefits patients with intracerebral hemorrhage: systematic review and meta-analysis. Stroke 2013;44:3044–3049.
8. Anderson CS, Heelley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355–2365.
9. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemahge. N Engl J Med 2016;375:1033–1043.
10. Schreuder FH, Sato S, Klijn CJ, et al. Medical management of intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2017;88:76–84.

11. Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage: current approaches to acute management. Lancet 2018;392:1257–1268.

12. Parry-Jones AR, Sammut-Powell C, Paroutoglou K, et al. An intracerebral haemorrhage care bundle is associated with lower case fatality. Ann Neurol 2019;86:495–503.

13. Hemphill JC III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral haemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015;46:2032–2060.

14. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral haemorrhage. Int J Stroke 2014;9:840–855.

15. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005;365:387–397.

16. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013;382:397–408.

17. Gregson BA, Broderick JP, Auer LM, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral haemorrhage. Stroke 2012;43:1496–1504.

18. Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety if minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet 2019;393:1021–1032.

19. Al-Shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol 2018;17:885–897.

20. Askenase MH, Sansing LH. Stages of the inflammatory response in pathology and tissue repair after Intracerebral hemorrhage. Semin Neurol 2016;36:288–297.

21. Rodríguez-Luna D, Coscojuela P, Rubiera M, et al. Ultrasound brain haematoma growth in active intracerebral haemorrhage. Neurology 2014;87:357–364.

22. Davis SM, Broderick J, Hennrici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral haemorrhage. Neurology 2006;66:1175–1181.

23. Morgenstern LB, Demchuk AM, Kim DH, et al. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology 2001;56:1294–1299.

24. Li Y, Wang J, Li Z, et al. Computed tomography angiography spot sign as an indicator for ultra-early stereotactic aspiration of intracerebral haemorrhage. World Neurosurg 2018;109:e136–e143.

25. Moher D, Altman DG, Liberati A, Tetzlaff J. PRISMA statement. Epidemiology 2011;22:128 author reply 128.

26. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Version 6.0. 2019. Available at: www.training.cochrane.org/handbook. Accessed April 23, 2020.

27. IntHout J, Ioannidis JP, Rovers MM, et al. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016;6:e010247.

28. Baker WL, White CM, Cappelleri JC, et al. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 2009;63:1426–1434.

29. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–1573.

30. Cho DY, Chen CC, Lee WY, et al. A new modified intracerebral hemorrhage score for treatment decisions in basal ganglia hemorrhage—a randomized trial. Crit Care Med 2008;36:2151–2156.

31. Hanley DF, Thompson RE, Muschelli J, et al. Safety and Efficacy of Minimally Invasive Surgery Plus Alteplase in Intracerebral Haemorrhage Evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol 2016;15:1228–1237.

32. Vespa P, Hanley D, Betz J, et al. ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for brain haemorrhage: a multicenter randomized controlled trial. Stroke 2016;47:2749–2755.

33. Zuccarello M, Brott T, Derex L, et al. Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study. Stroke 1999;30:1833–1839.

34. Batjer HH, Reisch JS, Allen BC, et al. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. Arch Neurol 1990;47:1103–1106.

35. Juvela S, Heiskanen O, Poranen A, et al. The treatment of spontaneous intracerebral hemorrhage: a prospective randomized trial of surgical and conservative treatment. J Neurosurg 1989;70:755–758.

36. Auer LM, Deinsberger W, Niederkom K, et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg 1989;70:530–535.

37. Teemstra OP, Evers SM, Lodder J, et al. Stereotactic Treatment of Intracerebral Hematoma by Means of a Plasminogen Activator: a multicenter randomized controlled trial (SICHPA). Stroke 2003;34:968–974.

38. Wang X, Yang S, Huang Y, et al. Effects of cranio puncture and drainage of intracerebral hemorrhage on brain edema and neurological outcome [in Chinese]. Chin J Contemp Neurol Neurosurg 2011;11:230–235.

39. Luo JB, Peng B, Quan W, et al. Therapeutic effects of aspiration with a directional soft tube and conservative treatment on mild hemorrhage in the basal ganglia [in Chinese]. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1352–1353.

40. Miller CM, Vespa P, Saver JL, et al. Image-guided endoscopic evacuation of spontaneous intracerebral hemorrhage. Surg Neurol 2008;69:441–446.

41. Young ZK, Kyo HK. Even in patients with a small hemorrhagic volume, stereotactic-guided evacuation of spontaneous intracerebral hemorrhage improves functional outcome. J Korean Neurosurg Soc 2009;46:109–115.

42. Wang WZ, Jiang B, Liu HM, et al. Minimally invasive craniopuncture and drainage on activities of daily living during the chronic period following spontaneous putaminal hemorrhage: a randomized study. Chin J Neurosurg 2004;101:420.

43. Pantazis G, Tsitsopoulos P, Mihas C, et al. Early surgical treatment vs conservative management for spontaneous supratentorial intracerebral hematoma: a prospective randomized study. Surg Neurol 2006;66:492–501; discussion 501.

44. Hatton N, Katayama Y, Maya Y, Gatherer A. Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage: a randomized study. J Neurosurg 2004;101:417–420.

45. Wei PB, You C, Chen H, et al. Three treatments for moderate hyperensive intracerebral hemorrhage: a comparative therapeutic. Chin J Cerebrovasc Dis 2010;7:519–522.

46. Morgenstern LB, Frankowski RF, Shedden P, et al. Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial. Neurology 1998;51:1359–1363.

47. Bhaskar MK, Kumar R, Ojha B, et al. A randomized controlled study of operative versus nonoperative treatment for large spontaneous
supratentorial intracerebral hemorrhage. Neurol India 2017;65:752–758.

48. Mitchell P, Gregson B. Surgery for ICH after MISTIE III. Br J Neurosurg 2019;33:117–118.

49. Scaggiante J, Zhang X, Mocco J, Kellner CP. Minimally invasive surgery for intracerebral hemorrhage. Stroke 2018;49:2612–2620.

50. Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2014;372:11–20.

51. Ramanan M, Shankar A. Minimally invasive surgery for primary supratentorial intracerebral haemorrhage. J Clin Neurosci 2013;20:1650–1658.

52. Yao Z, Hu X, You C, et al. Effect and feasibility of endoscopic surgery in spontaneous intracerebral hemorrhage: a systematic review and meta-analysis. World Neurosurg 2018;13:348–356.

53. Al-Shahi Salman RA, Klijn CJM, Selim M. Minimally invasive surgery plus alteplase for intracerebral haemorrhage. Lancet 2019;393:965–967.